Endologix Receives CE Mark Approval for Nellix Sealing System With Refined Indications for Use

 

September 21, 2017—Endologix, Inc. announced that CE Mark approval was granted for its Nellix endovascular aneurysm sealing system with refined indications for use.

The company stated that following an extensive review of supporting clinical data, it was determined that the refined indications for use for the Nellix system met the applicable safety and clinical performance requirements for CE Mark approval.

This approval of the refined indications for use enable physicians and patients in Europe to continue to have access to the clinical benefits of complete aneurysm sealing, including low rates of endoleaks and all-cause mortality, noted Endologix in its announcement.

In the United States, Nellix is being studied under an investigational device exemption and is not currently available for commercial use.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.